Pharmaceuticals Global On demand · 24-48h

Global Indocyanine Green Market Strategic Research Report

Global Indocyanine Green Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Indocyanine Green Market
$92.852025
4.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: 25mg, 50mg

By Application: Ophthalmology, Neurosurgery, Liver Diseases, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Pulsion Medical Systems AG, Dandong Yichuang Pharmaceutical, Daiichi Sankyo Company, SERB, Santen Pharmaceutical, Diagnostic Green, McKesson Corp, OriFarm, Jeil Pharmaceutical, Aurolab, Cellbion, Eisai

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 124 pages
Market size 2025
$92.85
Million USD
Forecast CAGR
4.8%
2025-2032
Forecast 2032
$128.9
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Indocyanine Green market size is predicted to grow from US$ 92.85 million in 2025 to US$ 129 million in 2032; it is expected to grow at a CAGR of 4.8% from 2026 to 2032.

Indocyanine green (ICG) (CAS 3599-32-4), a cyanine dye used in medical diagnostics to determine cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography. It is a sterile, lyophilized green powder with a peak spectral absorption at 800 nm. These infrared frequencies penetrate retinal layers, allowing ICG angiography to image deeper patterns of circulation than fluorescein angiography.

Europe is the largest Indocyanine Green (CAS 3599-32-4) market with about 52% market share. USA is follower, accounting for about 22% market share.The key manufacturers are Pulsion Medical Systems AG,Dandong Yichuang Pharmaceutical, Diagnostic Green, SERB, Daiichi Sankyo Company, Santen Pharmaceutical, Aurolab, Eisai, etc. Top 3 companies occupied about 60% market share.

Market drivers

Increasing demand for precision medicine

The popularization of fluorescence navigation technology in tumor surgery (such as da Vinci robotic surgery) has made ICG a key reagent for intraoperative imaging. High-incidence tumors such as liver cancer and breast cancer have driven demand (China has more than 400,000 new cases of liver cancer each year).

Technology upgrade and expansion of indications

ICG combined with near-infrared imaging (NIR) technology has been expanded to new scenarios such as lymphangiography and gastrointestinal anastomosis. Nanocarrier technology improves ICG stability and prolongs imaging time (such as tumor-targeted ICG nanoformulations).

Popularization of minimally invasive surgery

The proportion of minimally invasive surgeries such as laparoscopy and thoracoscopy has increased, and the demand for ICG imaging has surged.

This report presents a comprehensive overview of the global Indocyanine Green market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • 25mg
  • 50mg

Segment by Application

  • Ophthalmology
  • Neurosurgery
  • Liver Diseases
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Indocyanine Green market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Ophthalmology, Neurosurgery, Liver Diseases evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Indocyanine Green Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$92.85
2025
Forecast
$128.9
2032
CAGR
4.8%
2025–2032
Regiões
5
global
Key companies
Pulsion Medical Systems AGDandong Yichuang PharmaceuticalDaiichi Sankyo CompanySERBSanten PharmaceuticalDiagnostic GreenMcKesson CorpOriFarm
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
25mg50mg
By Application
OphthalmologyNeurosurgeryLiver DiseasesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 25mg
  • 3.1.3 50mg
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Ophthalmology
  • 4.1.3 Neurosurgery
  • 4.1.4 Liver Diseases
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Pulsion Medical Systems AG
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Dandong Yichuang Pharmaceutical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Daiichi Sankyo Company
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 SERB
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Santen Pharmaceutical
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Diagnostic Green
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 McKesson Corp
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 OriFarm
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Jeil Pharmaceutical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Aurolab
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Cellbion
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Eisai
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Indocyanine Green market?
The global Indocyanine Green market is estimated at US$ 92.85 million in 2025 (base year) and is projected to reach US$ 129 million by 2032.
What is the forecast CAGR for the Indocyanine Green market?
The market is expected to grow at a CAGR of 4.8% from 2026 to 2032, expanding from US$ 92.85 million in 2025 to US$ 129 million in 2032, roughly 1.4 times its base-year value.
What is Indocyanine Green?
Indocyanine green (ICG) (CAS 3599-32-4), a cyanine dye used in medical diagnostics to determine cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography. It is a sterile, lyophilized green powder with a peak spectral absorption at 800 nm. These infrared frequencies penetrate retinal layers, allowing ICG angiography to image deeper patterns of circulation than fluorescein angiography.
How is the Indocyanine Green market segmented by type?
By type, the market is segmented into 25mg and 50mg.
What are the key applications of Indocyanine Green?
Key applications covered include Ophthalmology, Neurosurgery, Liver Diseases and Others.
Which companies are profiled in the Indocyanine Green market report?
Key players profiled include Pulsion Medical Systems AG, Dandong Yichuang Pharmaceutical, Daiichi Sankyo Company, SERB, Santen Pharmaceutical, Diagnostic Green, McKesson Corp and OriFarm, among 12 companies covered in total.
What geographies does the Indocyanine Green market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Indocyanine Green?
High-incidence tumors such as liver cancer and breast cancer have driven demand (China has more than 400,000 new cases of liver cancer each year).
Who should buy the Indocyanine Green market report?
The report is intended for manufacturers and solution providers, distributors and end users in Ophthalmology, Neurosurgery and Liver Diseases, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Indocyanine Green market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.